<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8406612</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1580</journal-id>
<journal-id journal-id-type="nlm-ta">Appl Microbiol Biotechnol</journal-id>
<journal-id journal-id-type="iso-abbrev">Appl. Microbiol. Biotechnol.</journal-id>
<journal-title-group>
<journal-title>Applied microbiology and biotechnology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0175-7598</issn>
<issn pub-type="epub">1432-0614</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31203417</article-id>
<article-id pub-id-type="pmc">7066869</article-id>
<article-id pub-id-type="doi">10.1007/s00253-019-09958-x</article-id>
<article-id pub-id-type="manuscript">NIHMS1569871</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Two-week administration of engineered <italic>Escherichia coli</italic> establishes persistent resistance to diet induced obesity even without antibiotic pretreatment.</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dosoky</surname>
<given-names>Noura</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zhongyi</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McMillan</surname>
<given-names>Clara</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flynn</surname>
<given-names>C. Robb</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Davies</surname>
<given-names>Sean S.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9879-8062</contrib-id>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="corresp" rid="CR1">#</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Division of Clinical Pharmacology and Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA</aff>
<aff id="A2"><label>b</label>Division of Surgery, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA</aff>
<author-notes>
<corresp id="CR1"><label>#</label>Address correspondence to Sean S. Davies, 556B RRB, Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN37232-6602, USA. Phone: 615.322.5049; <email>sean.davies@vanderbilt.edu</email>.</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P34"><bold>Conflict of interest:</bold> Author 2 (ZC) and Author 6 (SSD) have a patent pending for the use of engineered bacteria expressing NAPE or NAE for treating obesity. Authors 1, 3, 4, and 5 declare that they have no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>4</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>8</month>
<year>2020</year>
</pub-date>
<volume>103</volume>
<issue>16</issue>
<fpage>6711</fpage>
<lpage>6723</lpage>
<!--elocation-id from pubmed: 10.1007/s00253-019-09958-x-->
<abstract id="ABS1">
<p id="P1">Adverse alterations in the composition of the gut microbiota have been implicated in the development of obesity and a variety of chronic diseases. Re-engineering the gut microbiota to produce beneficial metabolites is a potential strategy for treating these chronic diseases. <italic>N</italic>-acyl-phosphatidylethanolamines (NAPEs) are a family of bioactive lipids with known anti-obesity properties, Previous studies showed that administration of <italic>Escherichia coli</italic> Nissle 1917 (EcN) engineered with <italic>Arabidopsis thaliana</italic> NAPE synthase to produce NAPEs imparted resistance to obesity induced by a high fat diet that persisted after ending their administration. In prior studies, mice were pre-treated with ampicillin prior to administering engineered EcN for 8 weeks in drinking water. If use of antibiotics and long-term administration are required for beneficial effects, implementation of this strategy in humans might be problematic. Studies were therefore undertaken to determine if less onerous protocols could still impart persistent resistance and sustained NAPE biosynthesis. Administration of engineered EcN for only two weeks without pre-treatment with antibiotics sufficed to establish persistent resistance. Sustained NAPE biosynthesis by EcN was required as antibiotic treatment after administration of the engineered <italic>EcN</italic> markedly attenuated its effects. Finally, heterologous expression of human Phospholipase A/acyl-transferase-2 (PLAAT2) in EcN provided similar resistance to obesity as heterologous expression of <italic>A. thaliana</italic> NAPE synthase, confirming that NAPEs are the bioactive mediator of this resistance.</p>
</abstract>
<kwd-group>
<kwd>Gut microbiota</kwd>
<kwd>engineered bacteria</kwd>
<kwd>N-acyl-phosphatidylethanolamines</kwd>
<kwd>N-acyl-ethanolamides</kwd>
<kwd>N-acyltransferases</kwd>
<kwd>antibiotics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>